Interferon-α enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma

Journal of Immunotherapy

Volumn 31, Issue 7, 2008, Pages 599-606

  Zhu, Yifan ^a   Tibensky, Igor ^a   Schmidt, Jan ^a   Ryschich, Eduard ^a   Märten, Angela ^a,b  

^a Department of Surgery ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoimmunotherapy; Interferon ; Pancreatic carcinoma

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADD ON THERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRAFT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DIARRHEA; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM; EXTERNAL BEAM RADIOTHERAPY; FEMALE; IMMUNOMODULATION; IMMUNOREACTIVITY; LEUKOCYTE; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LIVER METASTASIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MEMORY T LYMPHOCYTE; MICROSCOPY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS ADENOCARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION INJURY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; WEIGHT REDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL ADHESION; CELL MOTION; IMMUNOLOGY; LIVER TUMOR; METABOLISM; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; RADIOTHERAPY; SECRETION; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; CYTOKINES; FLUOROURACIL; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 63849148850     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181818769     Document Type: Article

References (28)

1. Raraty MG, Magee CJ, Ghaneh P, et al. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002;41: 582-595.
2. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476-480.
3. Knaebel H, Mä rten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI [ISRCTN 62866759]. BMC Cancer. 2005;5.
4. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198-1205.
5. Iacopino F, Ferrandina G, Scambia G, et al. Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. Anticancer Res. 1996;16:1919-1924.
6. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489-2499.
7. Holsti LR, Mattson K, Niiranen A, et al. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol, Biol, Phys. 1987;13:1161-1166.
8. Kurzrock R, Talpaz M, Guttermann J. Interferons: Clinical Applications. Philadelphia: Lippincott; 1991:334-348.
9. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs. 2002;16:261-281.
10. Solorzano CC, Hwang R, Baker CH, et al. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res. 2003;9:1858-1867.
11. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999;189:521-530.
12. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93:1980-1991.
13. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64:358-367.
14. Ma J, Patrut E, Schmidt J, et al. Synergistic effects of interferonalpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroentero. 2005;11:1521-1528.
15. Schmidt J, Patrut EM, Ma J, et al. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother. 2006;55: 1396-1405.
16. Schmidt J, Jä ger D, Hoffmann K, et al. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother. 2007;30:108-115.
17. Schneider C, Schmidt T, Ziske C, et al. Tumorsuppression induced by macrophage activating lipopeptide in an ultrasound-guided syngeneic pancreatic carcinoma mouse model. Gut. 2003;53: 355-363.
18. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44: 717-726.
19. Ryschich E, Harms W, Loeffler T, et al. Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat. Int J Cancer. 2003;105:506-511.
20. Neoptolemos J, Stocken D, Friess H, et al. The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic cancer. N Engl J Med. 2004;350: 1200-1210.
21. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784-788.
22. Rovere P, Sabbadini MG, Vallinoto C, et al. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol. 1999;66:345-349.
23. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, crosspriming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170:4905-4913.
24. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002;62: 2353-2358.
25. Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature. 1974;249:654-656.
26. Lake R, Robinson B. Immunotherapy and chemotherapy- a practical partnership. Nat Rev Cancer. 2005;5:397-405.
27. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocytemacrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337-6343.
28. Schmidt J, Klempp C, Bü chler MW, et al. Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo. Cancer Immunol Immunother. 2006;55:31-38.